Genentech Inc.
Division of Roche
www.gene.com
Latest From Genentech Inc.
Deal Watch: Roivant Spins Out Arvelle, Licenses Epilepsy Candidate From SK Biopharma
Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.
Big Pharma CEOs Get Ready To Testify: Preparing For A No-Win Situation
Here is what to expect from – and some free advice for – seven industry executives as they prepare for a hearing on drug pricing in the Senate Finance Committee.
Almirall Extends Dermatology Reach With Dermira Lebrikizumab Deal
Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.
Keeping Track: CDER Approves Its First Two Novel Agents Of 2019
The latest drug development news and highlights from our US FDA Performance Tracker.
Company Information
- Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Gastrointestinal
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Ophthalmic
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Roche
- Senior Management
-
Alexander Hardy, CEO
Ed Harrington, CFO
Sandra J Horning, MD, EVP, Global Dev. & CMO - Contact Info
-
Genentech Inc.
Phone: (650) 225-1000
1 DNA Way
S. San Francisco, CA 94080
USA
Advertisement
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice